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The immune system is exposed to an enormous number 
of antigens in the intestine, including those derived from 
food and bacteria, yet mucosal immune responses are 
characterized by a lack of cell-mediated immune respon- 
siveness to these antigens. Indeed, oral exposure to anti- 
gen can lead to a subsequent state of systemic hyporeac- 
tivity to the fed antigen (Weiner, 1994) suggesting that 
there are regulatory mechanisms in place that actively 
prevent development of immune responses to antigens 
present in the gut. 
In the last 2 years, an impressive number of different 
models of inflammatory bowel disease (IBD) in mice and 
rats have been described. These can broadly be divided 
into three groups. First, mice with alterations in T cell sub- 
populations and T cell selection: T cell receptor-a (TCRa) 
chain-deficient mice, TCR6 chain-deficient mice, and 
major histocompatibility complex (MHC) class II gene- 
deficient mice (Mombaerts et al., 1993) SCID mice re- 
stored with CD45RBh’ CD4’ T cells (Morrissey et al., 1993; 
Powrie et al., 1993, 1994a), HLA-B27 transgenic rats 
(Hammer et al., 1990) and human CD3s transgenic mice, 
transplanted with normal Fl bone marrow cells (Hollander 
et al., 1995a). Second, mice with targeted disruption of 
cytokine genes: interleukin-2 (IL-2) (Sadlack et al., 1993) 
IL-10 (Kuhn et al., 1993) and transforming growth factor- 
51 (TGF61)-deficient mice (Shull et al., 1992; Kulkarni et 
al., 1993). Third, mice lacking signaling proteins; G protein 
subunit Ga3-deficient mice (Rudolph et al., 1995). While 
these models at first sight look very different, they all in- 
volve manipulations that perturb the immune system. In- 
deed, all of these models of IBD may induce disease by 
the common feature of disrupting a Tcell-dependent regu- 
latory system that normally functions to protect the gut 
from cell-mediated immune attack. 
T Cells Are Mandatory for Regulation of Colitis 
but Optional for Its Induction 
Data from a number of these experimental models of IBD 
indicate that a subpopulation of T cells plays a critical role 
in the normal regulation of intestinal immune responses. 
Colitis developed in mice that lacked the majority of a6’ 
T cells due to targeted disruption of either the TCR a chain 
or TCR 6 chain genes, as well as in MHC class II-deficient 
mice that lack class II-restricted CD4’T cells (Mombaerts 
et al., 1993). In contrast, TCR 6 chain-deficient mice, 
which lack the yS+ subset of T cells, but have a normal 
population of up’ T cells, remained disease free (Mom- 
baet-ts et al., 1993). Taken together, these data identify a 
population of class II-restricted up+ T cells as important 
for the prevention of colitis. Direct evidence that a subpop- 
ulation of normal CD4+ T cells can mediate such an immu- 
noregulatory role is evident from the finding that colitis 
induced in C.B-17 SCID mice by transfer of CD45RBhi 
CD4’ T cells from normal BALB/c mice was completely 
prevented by cotransfer of the reciprocal CD45RBb CD4+ 
T cell population (Powrie et al., 1993, 1994a). 
Aberrant T cell development may also explain the colitis 
that developed in CD~E transgenic mice (HollBnder et al., 
1995a). Overexpression of the human CD3& gene in mice 
led to a very early arrest in T cell development and a highly 
abnormal thymic microenvironment. As a consequence, 
these mice lacked both T and natural killer (NK) cells in 
the periphery (Wang et al., 1994; Holliinder et al., 1995b). 
Transplantation of these mice with normal Tcell-depleted 
Fl bone marrow led to severe colitis, which was prevented 
when CD3s transgenic mice were simultaneously trans- 
planted with normal fetal thymus (Holllinder et al., 1995a). 
While there are many possible explanations for these re- 
sults, one possibility is that T cell development through 
the aberrant thymus resulted in a population of T cells that 
lacked the regulatory component and thus were able to 
induce a pathogenic response in the intestine. It is clear 
from the SCID transfer model that normal CD4’ T cells 
are capable of inducing colitis if the regulatory CD4+ sub- 
population is removed (Morrissey et al., 1993; Powrie et 
al., 1993, 1994a). Colitis is prevented in the presence of 
a normal fetal thymus, as under these circumstances se- 
lection/development of a regulatory T cell population oc- 
curs, which inhibits disease induction. This hypothesis is, 
of course, amenable to experimental test. 
If this hypothesis is correct, the CD3s transgenic experi- 
ments raise the interesting question of why regulatory T 
cells fail to be selected or develop in the aberrant thymus, 
whereas pathogenic T cells develop normally. Regulatory 
cells may require the presence of certain signals in the 
thymus for their development that are lacking in the aber- 
rant thymus. Alternatively, the balance between the devel- 
opment of pathogenic T cells and regulatory cells may 
depend on T cell numbers. A number of autoimmune dis- 
eases develop under situations of relative T cell lympho- 
poenia (Penhale et al., 1976, Sakaguchi and Sakaguchi, 
1969) suggesting the development of regulatory cells may 
require higher numbers of T cells, reflecting perhaps a 
requirement for a critical threshold of cytokine production. 
The presence of the normal thymus in the bone marrow- 
reconstituted CD3s transgenic mice may restore T cell 
numbers to normal levels, enabling the development of 
the regulatory population. 
In contrast with the regulation of colitis, which was de- 
pendent on CD4’ T cells, there may be several cell types 
that can mediate disease induction. T cells are clearly 
capable of such a function as colitis, which, developed in 
bone marrow-restored CD3s transgenic mice, could be 
adoptively transferred to immunodeficient recipients by 
transfer of T cells isolated from the spleen of mice with 
colitis (Hollander et al., 1995a), and colitis in IL-2deficient 
mice was shown to be dependent on T cells but not B cells 
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(Ma et al., 1995). The CD4’ T cell subset is sufficient to 
induce colitis as transfer of CD45RBhi splenic CD4+ T cells 
from normal coisogenic donors to immunodeficient mice 
led to severe colitis (Morrissey et al., 1993; Powrie et al., 
1993, 1994a); however, these cells do not appear to be 
absolutely required, as mice lacking the majority of either 
up’ or class II-restricted T cells also developed colitis 
(Mombaerts et al., 1993). Severity of disease was signifi- 
cantly reduced when mice lacking af3+T cells werecrossed 
with mice lacking y6+ T cells, suggesting the latter may 
also play a role in the pathogenesis of colitis. Interestingly, 
mild disease still developed in mice that lacked up’ as 
well as yS+ T cells, indicating that cells other than T cells, 
such as 6 cells or NK cells, may be involved in the disease 
process (Mombaerts et al., 1993; Strober and Ehrhardt, 
1993). 
Cytokines in the Induction and Regulation of Colitis 
To dissect further the mechanisms of colitis induction and 
protection, it is important to establish the cytokines that 
are involved in the pathogenic and regulatory pathways. 
In a number of models, there is evidence to suggest a 
differential activation of the T helper 1 (Thl) cytokines, 
interferon-y (IFN?), and tumor necrosis factor-a (TNFa) in 
mice with colitis (Powrie et al., 1993; Rudolph et al., 1995). 
IFNy and TNF were shown to be involved directly in the 
pathogenesis of colitis in CD45RBhi CD4+ T cells restored 
SCID mice, as disease was prevented by administration 
of anti-IFNy monoclonal antibody (MAb) and significantly 
reduced in severity by treatment with anti-TNF MAb (Pow- 
rie et al., 1994b). CD4+ T cells isolated from the lamina 
propria of CD45RB”’ CD4+ T cell restored SCID mice with 
colitis were shown to be an important source of IFNy in 
the lesion (Powrie et al., 1994b). However, a number of 
other cell types produce IFNy, including NK cells, y6 T 
cells, and CD8 T cells (Trinchieri and Perrussia, 1985) 
and, in some models, these cell populations may be a 
more important source of this cytokine. It is not clear 
whether IFNy acts directly, causing damage to colonic 
epithelial cells (Targan et al., 1991), or acts primarily to 
activate macrophages with the subsequent production of 
inflammatory mediators such as reactive oxygen and nitro- 
gen intermediates, IL-l, IL-8, IL-12, and TNFa, many of 
which have been shown to cause intestinal damage 
(Braegger and MacDonald, 1994). 
The regulatory T cell population may prevent develop- 
ment of disease by production or induction of a cytokine 
repertoire that antagonizes the development and/or ef- 
fector function of cells involved in an IFNydependent, 
TNFadependent inflammatory response. IL-10 appears 
to play an important role in this regulatory pathway as 
IL-10 deficient mice developed colitis (Kuhn et al., 1993) 
and administration of recombinant IL-10 significantly in- 
hibited development of colitis in SCID mice restored with 
CD45RB”’ CD4’ T cells (Powrie et al., 1994b). IL-10 has 
been shown to antagonize Thl responses at a number of 
levels, including cytokine production by T cells and pro- 
duction of inflammatory mediators by macrophages (Moore 
et al., 1993). 
In addition to IL-lo, TGF8 also plays a pivotal role in 
the regulation of pathogenic inflammatory responses as 
TGFf31-deficient mice developed inflammatory lesions in 
a number of organs, including on some genetic back- 
grounds, the gastrointestinal tract (Shull et al., 1992; Kul- 
karni et al., 1993). TGF8 has been shown to be induced 
upon oral exposure to antigen and to be an important medi- 
ator of oral tolerance. Suppression of experimental allergic 
encephalomyelitis by transfer of CD4+ T cell clones gener- 
ated by oral exposure to myelin basic protein was inhibited 
by anti-TGFj3 MAb (Chen et al., 1994). Recently, protection 
from CD45RBhi CD4+ T cell-induced colitis in SCID mice 
by cotransfer of the CD45RB’O population was completely 
ablated by treatment of the recipients with anti-TGF8 MAb 
(Powrie et al., 1995), providing evidence for a central role 
for TGF8 in the control of inflammatory responses in the 
intestine. Whether TGF8 and IL-10 are components of a 
common regulatory pathway or represent distinct path- 
ways and whether in vivo these cytokines are produced 
by regulatory T cells themselves or induced in other cell 
types is presently unknown. 
Th2 cells and their cytokines have been shown to inhibit 
the development and effector functions of Thl cells in a 
number of infectious diseases (Sher et al., 1992). Th2- 
mediated suppression of Thl responses is also thought 
to be involved in the regulation of autoimmune disease 
(Fowell and Mason, 1993; Scott et al., 1994), although 
there is no definitive evidence on this point. However, the 
data presently available argue against a prominent role 
for IL-4 in the regulation of IBD, as IL-4-deficient mice 
do not develop colitis (Kuhn et al., 1991) and systemic 
administration of recombinant IL-4 had no effect on colitis 
development in T cell-restored SCID mice (Powrie et al., 
1994b). As Th2 responses have been shown to be depen- 
dent on IL-4 (Kopf et al., 1993) these data suggest that 
the regulatory Tcell population is independent of classical 
Th2 cells. 
Development of colitis in IL-2deficient mice suggests 
that IL-2 is somehow involved in the immunoregulatory 
pathway (Sadlack et al., 1993). Whether IL-2 is required 
for the generation of the regulatory population or directly 
involved in inhibition of the inflammatory response is not 
known. 
Colitis, A Dysregulated Immune Response 
to Components of the Normal Flora 
One of the obvious questions that arises from these stud- 
ies is why do such a diverse set of immune manipulations 
result in the development of chronic inflammation, which, 
in most models, is primarily restricted to the large intes- 
tine? One of the differences between the small and large 
intestine is that the latter contains the bulk of the bacterial 
flora, raising the possibility that colitis develops as a result 
of dysregulated cell-mediated immune responses against 
components of the enteric flora. In support of this, IL-2- 
deficient mice(Sadlacket al., 1993) and HLA-B27transgenic 
rats (Taurog et al., 1994) failed to develop intestinal inflam- 
mation when they were maintained under germ-free condi- 
tions, implicating the normal flora as a necessary compo- 
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nent of disease. Further, wasting disease that developed 
in CD45RB”’ CD4+ restored SCID mice was also signifi- 
cantly alleviated by treatment with antibiotics (Morrisssey 
and Charrier, 1994). 
Precisely how bacterial flora are involved in the disease 
process is unknown. There are several, not necessarily 
mutually exclusive, possibilities. First, pathogenic T cells 
respond directly to bacterial antigens. In some circum- 
stances these may cross-react with self-antigens. Second, 
T cells with a number of specificities are activated by bac- 
terial superantigens. Injection of superantigen has been 
shown to induce relapses in mice with experimental aller- 
gicencephalomyelitis(Brockeetal., 1993).Third, bacterial 
products such as cell wall components and lipopolysac- 
charide stimulate components of the innate immune sys- 
tem with the production of cofactors, such as IL-12, that 
tip the balance towards development of Thl responses to 
gut antigens, which could include both self- and nonself- 
antigens. The local cytokine milieu has been shown to 
play an important role in T cell differentiation in vitro. For 
example, heat killed preparations of Listeria monocyto- 
genes led to the production of IL-12 by macrophages, 
which skewed antigen-specific T cell differentiation against 
an unrelated antigen towards a Thl phenotype (Hsieh et 
al., 1993). 
A Model 
The animal models of colitis have generated a lot of infor- 
mation, which, if taken together, form the outline of a 
model that may begin to explain immune regulation in the 
intestine. Under normal circumstances, cell-mediated im- 
mune responses to gut antigens are actively prevented 
from developing, owing to a regulatory population of T 
cells contained within the CD45RB” subset of CD4’ T 
cells, which are dependent for their inhibitory function on 
IL-lo, TGFP, or both. In the absence of these cells, im- 
mune regulation breaks down and IFNy- and TNFa-depen- 
dent inflammatory responses, possibly involving multiple 
cell types, develop to components of the enteric flora or 
gut antigens (or both) (Figure 1). 
Future Directions 
Many questions remain to be answered. Some of the more 
important ones include the following: do the IL-lO/TGFP- 
dependent regulatory cells represent a distinct lineage of 
cells with a specialized function, selected in the thymus 
or do they develop from naive mature peripheral T cells 
after antigen exposure in the periphery? Precisely how is 
the bacterial flora involved in disease induction and are 
the regulatory cells also dependent on the flora for their 
development and effector function? Is regulation of patho- 
genic T cells at the level of their development or effector 
function? Is this regulatory pathway applicable to other 
Thl -mediated pathogenic diseases? 
The spontaneous models of IBD have revealed potent 
immune regulatory pathways involving T cell subsets and 
cytokines that are critical for the regulation of mucosal 
immune responses. Further characterization of the cellu- 
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Figure 1. CD4+ T Cell-Dependent Regulation of Immune Responses in the Intestine 
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lar and molecular interactions that constitute this pathway 
may provide important information for the design of thera- 
peuticstrategies that harness the power of natural immune 
regulatory mechanisms and may be useful for treatment 
of diseases with a Thl-mediated pathogenesis. 
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